News Sentiment

OVID sentiment intelligence

Ovid Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.52 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-6.3% over one week, +9.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

FEDERATED HERMES, INC. Increases Stake in Ovid Therapeutics Inc

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -6.3% Price reacting lower
Trend fit Trend active 9.6% over four weeks
Fair value 31.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 31
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 8
Stock Titan 6
GlobeNewswire 5
www.marketscreener.com 5
simplywall.st 4
Investing.com Nigeria 2
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 15
Analyst action 3
Balance sheet 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-54 of 54
TradingKey Direct company coverage

Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Ovid Therapeutics Inc (OVID), highlighting its current risk score of 2.74, ranking it 193 out of 388 in the Biotechnology & Medical Research industry. The company's beta of 0.17 suggests it tends to underperform in up-trending markets b

Tone
Negative 38/100
Event
Analyst action
Published
18 Jun 2026 06:40
Source
TradingKey